Home Cart Sign in  
Chemical Structure| 2449301-27-1 Chemical Structure| 2449301-27-1

Structure of GSK2643943A
CAS No.: 2449301-27-1

Chemical Structure| 2449301-27-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

GSK2643943A is a deubiquitinase (DUB) inhibitor targeting USP20. GSK2643943A has affinity for USP20/Ub-Rho, with an IC50 value of 160 nM. GSK2643943A exhibits anti-tumor activity and can be used in research on oral squamous cell carcinoma (OSCC).

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of GSK2643943A

CAS No. :2449301-27-1
Formula : C17H12FN3
M.W : 277.30
SMILES Code : FC1=CC=CC(/C=C/C2=CC3=C(C=C2)C(C#N)=C(N)N3)=C1
MDL No. :N/A

Safety of GSK2643943A

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
SCC7 cells 1 μM To evaluate the effect of GSK2643943A on oHSV-1 T1012G virus replication in SCC7 cells, results showed GSK treatment significantly increased virus yields Mol Ther Oncolytics. 2021 Nov 11;23:477-487
SCC9 cells 1 μM To evaluate the effect of GSK2643943A on oHSV-1 T1012G virus replication in SCC9 cells, results showed GSK treatment significantly increased virus yields and viral protein expression Mol Ther Oncolytics. 2021 Nov 11;23:477-487

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c nude mice SCC9 tumor model Intraperitoneal injection 5 mg/kg Once daily for 6 days To evaluate the anti-tumor efficacy of GSK2643943A combined with oHSV-1 T1012G treatment in SCC9 tumors, results showed combined treatment significantly reduced tumor volume Mol Ther Oncolytics. 2021 Nov 11;23:477-487

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.61mL

0.72mL

0.36mL

18.03mL

3.61mL

1.80mL

36.06mL

7.21mL

3.61mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories